CALCILEAP 0.25

CALCILEAP 0.25 mcg (Calcitriol 0.25 mcg Tablets)

PRESENTATION

CALCILEAP 0.25 mcg (Calcitriol 0.25 mcg Tablets) is available as 1 x 10 x 10 Tablets/Box

DESCRIPTION

Calcitriol (1, 25 ( OH ) Vitamin D ) in Kidney Disease Calcitriol measurement is most helpful in the treatment and monitoring of chronic kidney disease ( CKD ). A deficit of calcitriol is an important factor leading to the uncontrolled secretion of parathyroid hormone (PTH) resulting in secondary hyperparathyroidism ( 2-HPTH ).  Calcitriol or the biologically active Vitamin D metabolites control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. They act directly on bone cells (osteoblasts) to stimulate skeletal growth and on the parathyroid glands to suppress PTH synthesis and secretion.

INDICATIONS AND USAGE

CALCILEAP 0.25 mcg (Calcitriol) is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.

DOSAGE 

The recommended initial dose of Calcitriol 0.25 mcg is 0.25 to 0.50 mcg as tablets orally.

CONTRAINDICATIONS

CALCILEAP 0.25 mcg (Calcitriol) should not be given to patients with hypercalcemia or evidence of vitamin D toxicity.

CALCILEAP 0.25 mcg (Calcitriol) is contraindicated in patients with previous hypersensitivity to calcitriol or any of its excipients.